TICKERNOMICS Sign up
Last Update: 2023-12-23 06:04:07
Lipocine Inc. ( LPCN ) https://www.lipocine.com
2.92USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
-57.59%
LPCN
SPY
30.72%
-87.80%
LPCN
SPY
112.82%
-86.24%
LPCN
SPY
201.04%
-97.92%
LPCN
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
15.48
-4.30
0.00
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.95
2.23
0.69
-74.27
0.00
0.25
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
225.60
192.21
-265.35
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
9.9872
-289.06
-54.11
1.48
Other Earnings and Cash Flow Stats:
Lipocine Inc. ( LPCN ) Net Income TTM ($MM) is -15.00
Lipocine Inc. ( LPCN ) Operating Income TTM ($MM) is -16.84
Lipocine Inc. ( LPCN ) Owners' Earnings Annual ($MM) is 0.00
Lipocine Inc. ( LPCN ) Current Price to Owners' Earnings ratio is 0.00
Lipocine Inc. ( LPCN ) EBITDA TTM ($MM) is -15.99
Lipocine Inc. ( LPCN ) EBITDA Margin is -265.35%
Capital Allocation:
Lipocine Inc. ( LPCN ) has paid 0.00 dividends per share and bought back 83.47964 million shares in the past 12 months
Lipocine Inc. ( LPCN ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
Lipocine Inc. ( LPCN ) Interest-bearing Debt ($MM) as of last quarter is 0
Lipocine Inc. ( LPCN ) Annual Working Capital Investments ($MM) are 3
Lipocine Inc. ( LPCN ) Book Value ($MM) as of last quarter is 22
Lipocine Inc. ( LPCN ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Lipocine Inc. ( LPCN ) has 4 million in cash on hand as of last quarter
Lipocine Inc. ( LPCN ) has 2 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Lipocine Inc. ( LPCN ) has 5 common shares outstanding as of last quarter
Lipocine Inc. ( LPCN ) has 0 million USD of preferred stock value
Academic Scores:
Lipocine Inc. ( LPCN ) Altman Z-Score is -8.12 as of last quarter
Lipocine Inc. ( LPCN ) Piotroski Score is 5.00 as of last quarter
Corporate Governance:
Lipocine Inc. ( LPCN ) largest shareholder is Tower Research Capital LLC owning 254 shares at 0.00 ($MM) value
Mahesh V Patel(an insider) Bought 8706 shares of Lipocine Inc. ( LPCN ) for the amount of $43791.18 on 2023-05-25
2.76% of Lipocine Inc. ( LPCN ) is held by insiders, and 9.60% is held by institutions
Lipocine Inc. ( LPCN ) went public on 2013-10-22
Other Lipocine Inc. ( LPCN ) financial metrics:
FCF:-11.71
Unlevered Free Cash Flow:0.00
EPS:-5.03
Operating Margin:225.60
Gross Profit Margin:192.21
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-118.34
Beta:1.48
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Lipocine Inc. ( LPCN ) :
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1154 for postpartum depression; LPCN 2101 for women with epilepsy; and LPCN 1148, a novel prodrug of testosterone, testosterone laurate for the management of decompensated cirrhosis. It also develops LPCN 1144, an oral prodrug of androgen receptor modulator for the treatment of non-cirrhotic non-alcoholic steatohepatitis, which has completed Phase II testing; LPCN 1111, an oral TRT product of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical testing; and LPCN 1107, an oral hydroxy progesterone caproate product for the prevention of recurrent preterm birth. Lipocine Inc. is headquartered in Salt Lake City, Utah.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.